Phase II Study of Tepotinib + Gefitinib (TEP+GEF) in MET-positive (met+)/epidermal Growth Factor Receptor (Egfr)-Mutant (MT) Non-Small Cell Lung Cancer (NSCLC).
Y. Cheng,J. Zhou,S. Lu,Y. Zhang,J. Zhao,H. Pan,Y-M. Chen,C-F. Chian,R. Bruns,A. Johne,J. Scheele,Y-L. Wu
DOI: https://doi.org/10.1093/annonc/mdy292
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: NSCLC can acquire resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via MET activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. TEP is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of TEP+GEF vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients (pts) with MET+/EGFR+T790M- NSCLC (NCT01982955). Methods: Asian pts with advanced MET + (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1st-line EGFR TKI and ECOG performance status 0–1 were eligible. Tumors had an EGFR-activating mutation (T790M-). Pts received TEP+GEF 500/250mg once-daily. Primary endpoint: progression-free survival (PFS by investigator). Secondary endpoints: safety, antitumor activity, pharmacokinetics. Results: Due to low recruitment, enrolment was halted after 55 pts were randomized to TEP+GEF (n = 31) or chemotherapy (n = 24): male n = 23, median age 60.4 (range 42–82) years. There was a numeric trend towards TEP+GEF on PFS in the intent-to-treat analysis set (hazard ratio [HR]: 0.71 [0.36, 1.39]), driven by the IHC3 + (HR: 0.35 [0.17, 0.74]) and gene-amplified (HR: 0.17 [0.05, 0.57]) pts (Table) confirming these as predictive biomarkers as indicated by phase 1b data. All pts had treatment-related (TR) treatment-emergent adverse events (TEAEs). In the TEP+GEF vs chemotherapy arms, respectively, 9.7 vs 4.3% had TEAEs leading to permanent discontinuation, 3.2 vs 0% had TEAEs leading to death (none were TRTEAEs), 16.1 vs 30.4% had serious TRTEAEs, 51.6 vs 52.2% had Grade ≥3 TRTEAEs, 12.9 vs 8.7% had a TRTEAE of special interest (lipase/amylase increase ≥3). Conclusions: TEP+GEF shows promising antitumor activity in pts with MET protein overexpression (IHC3+) and gene amplification EGFR-MT NSCLC and was generally well-tolerated. This positive signal warrants further exploration in this pt population. Clinical trial identification: NCT01982955. Editorial acknowledgement: Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by Lisa Jolly PhD of Bioscript Science (Macclesfield, UK). Legal entity responsible for the study: Merck KGaA. Funding: Merck KGaA. Disclosure: S. Lu: Research support: AstraZeneca; Speaker fees: AstraZeneca, Eli Lilly, Roche, Pfizer; Advisor, consultant role: AstraZeneca, Hutchison MediPharma, Simcere, BMS, Roche, Pfizer. R. Bruns, A. Johne, J. Scheele: Employee: Merck KGaA. Y-L. Wu: Speaker fees: AstraZeneca, Eli Lilly, Pfizer, Roche, Sanofi. All other authors have declared no conflicts of interest.Table: 1377OInvestigator assessedMedian PFS [90% CI], monthsObjective response rate, n (%) [90% CI]Overall intent-to-treat (MET + [IHC 2+/IHC 3+/gene amplification]/EGFR T790M-)Tepotinib + gefitinib (n = 31)4.86 [3.88, 6.87]14 (45.2) [29.7, 61.3]Pemetrexed + cisplatin/carboplatin (n = 24)4.37 [4.17, 6.80]8 (33.3) [17.8, 52.1]Stratified HR [90% CI] or odds ratio (OR) adjusted by randomization strata [90% CI]HR: 0.71 [0.36, 1.39]OR: 1.99 [0.56, 6.87]IHC3+/EGFR T790M-Tepotinib + gefitinib (n = 19)8.31 [4.11, 21.16]13 (68.4) [47.0, 85.3]Pemetrexed + cisplatin/carboplatin (n = 15)4.37 [4.11, 6.80]5 (33.3) [14.2, 57.7]Unstratified HR [90% CI] or OR [90% CI]0.35 [0.17, 0.74]4.33 [1.03, 18.33]Gene Amplification (GCN ≥5 or MET/CEP7 ratio ≥2/EGFR T790M-)Tepotinib + gefitinib (n = 12)21.16 [8.31, 21.16]8 (66.7) [39.1, 87.7]Pemetrexed + cisplatin/carboplatin (n = 7)4.21 [1.35, 6.97]3 (42.9) [12.9, 77.5]Unstratified HR [90% CI] or OR [90% CI]0.17 [0.05, 0.57]2.67 [0.37, 19.56]MET+: Met overexpression by immunohistochemistry (IHC2+ or 3+) and/or MET gene amplification and/or increased gene copy number (GCN ≥5 or MET/CEP7 ratio ≥2) by in-situ hybridisation Open table in a new tab MET+: Met overexpression by immunohistochemistry (IHC2+ or 3+) and/or MET gene amplification and/or increased gene copy number (GCN ≥5 or MET/CEP7 ratio ≥2) by in-situ hybridisation